Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2023 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at Stifel 2023 CNS Days

WATERTOWN, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
March 21, 2023 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

– Dosed first patient in IGNITE Phase 2 clinical trial to evaluate VGL101 in patients with ALSP – – Presented interim data from natural history study, ILLUMINATE, at Company-hosted ALSP KOL event...
March 02, 2023 16:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting

WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
January 03, 2023 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
December 15, 2022 16:01 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team

– Dr. David Gray brings nearly 20 years of preclinical and clinical research and drug development expertise in neurological diseases – – Dr. Spyros Papapetropoulos to depart Vigil to pursue a...
December 14, 2022 16:01 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP

CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
November 28, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022

CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
November 10, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update

–Announced interim topline data from Phase 1 trial of VGL101 in healthy volunteers– –On track to initiate Phase 2 proof-of-concept trial in ALSP patients this quarter– –Received Fast Track...
November 07, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
November 02, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

VGL101 demonstrated favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohortsVGL101 achieved dose dependent, robust and durable decreases in CSF...